LBX Pharmacy Chain Joint Stock Company (SHA:603883)
14.91
0.00 (0.00%)
Nov 18, 2026, 3:00 PM CST
SHA:603883 Revenue
LBX Pharmacy Chain Joint Stock Company had revenue of 5.65B CNY in the quarter ending September 30, 2026, with 6.73% growth. This brings the company's total for the last twelve months to 22.82B, up 2.80% year-over-year. In the year 2025, LBX Pharmacy Chain Joint Stock Company had annual revenue of 22.24B, down -0.54%. That makes LBX Pharmacy Chain Joint Stock Company the 3,482nd largest company in the world by revenue and 420th in China.
Revenue (ttm)
22.82B
Revenue Growth
+2.80%
P/S Ratio
0.49
Revenue / Employee
618.47K
Employees
36,892
Market Cap
11.32B
Revenue by Segment
- Retail 19.11B 60.0%
- Wholesale Division 12.31B 38.6%
- Others 442.02M 1.4%
Fiscal year ended Dec 31, 2025 See the full SHA:603883 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.24B | -120.99M | -0.54% |
| Dec 31, 2024 | 22.36B | -79.88M | -0.36% |
| Dec 31, 2023 | 22.44B | 2.26B | 11.21% |
| Dec 31, 2022 | 20.18B | 4.48B | 28.54% |
| Dec 31, 2021 | 15.70B | 1.73B | 12.38% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DaShenLin Pharmaceutical Group | 28.74B |
| Yifeng Pharmacy Chain | 25.38B |
| Luyan Pharma | 21.57B |
| Cachet Pharmaceutical | 17.25B |
| Yixintang Pharmaceutical Group | 17.03B |
| ShuYu Civilian Pharmacy Corp. | 10.85B |
| Jianzhijia Pharmaceutical Chain Group | 8.65B |
| Anhui Huaren Health Pharmaceutical | 5.91B |